miRNA expression in COVID-19

Kiarash Roustai Geraylow; Romina Hemmati; Sepideh Kadkhoda; Soudeh Ghafouri-Fard

doi:10.1016/j.genrep.2022.101641

miRNA expression in COVID-19

Gene Rep. 2022 Sep:28:101641. doi: 10.1016/j.genrep.2022.101641. Epub 2022 Jul 16.

Authors

Kiarash Roustai Geraylow¹, Romina Hemmati¹, Sepideh Kadkhoda², Soudeh Ghafouri-Fard³

Affiliations

¹ Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
² Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Coronavirus disease 2019 (COVID-19) is regarded as a challenge in health system. Several studies have assessed the immune-related aspect of this disorder to identify the host-related factors that affect the course of COVID-19. microRNAs (miRNAs) as potent regulators of immune responses have gained much attention in this regard. Recent studies have shown aberrant expression of miRNAs in COVID-19 in association with disease course. Differentially expressed miRNAs have been enriched in pathways related with inflammation and antiviral immune response. miRNAs have also been regarded as potential therapeutic targets in COVID-19, particularly for management of pathological consequences of COVID-19. In the current review, we summarize the data about dysregulation of miRNAs in COVID-19.

Keywords: ACE2, Angiotensin-converting enzyme 2; ARDS, Acute respiratory distress syndrome; COVID-19; COVID-19, Coronavirus disease 2019; HDAC, Histone deacetylate; HMVEC, Human Lung Microvascular Endothelial Cells; ORF, Open reading frame; ROC, Receiver operating characteristic; SARS-CoV-2; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; TLR, Toll-like receptor; TMPRSS2, Transmembrane protease serine 2; UTR, Untranslated region; hBMEC, Human brain microvascular endothelial cells; miRNA; miRNAs, microRNAs.

Publication types

Review